These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 20925551)

  • 1. Autoimmunity in a genetic disease—a cautionary tale.
    Moore MJ; Flotte TR
    N Engl J Med; 2010 Oct; 363(15):1473-5. PubMed ID: 20925551
    [No Abstract]   [Full Text] [Related]  

  • 2. Dystrophin immunity in Duchenne's muscular dystrophy.
    Mendell JR; Campbell K; Rodino-Klapac L; Sahenk Z; Shilling C; Lewis S; Bowles D; Gray S; Li C; Galloway G; Malik V; Coley B; Clark KR; Li J; Xiao X; Samulski J; McPhee SW; Samulski RJ; Walker CM
    N Engl J Med; 2010 Oct; 363(15):1429-37. PubMed ID: 20925545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune responses to dystropin: implications for gene therapy of Duchenne muscular dystrophy.
    Ferrer A; Wells KE; Wells DJ
    Gene Ther; 2000 Sep; 7(17):1439-46. PubMed ID: 11001363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune rejection of human dystrophin following intramuscular injections of naked DNA in mdx mice.
    Braun S; Thioudellet C; Rodriguez P; Ali-Hadji D; Perraud F; Accart N; Balloul JM; Halluard C; Acres B; Cavallini B; Pavirani A
    Gene Ther; 2000 Sep; 7(17):1447-57. PubMed ID: 11001364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping.
    Goyenvalle A; Vulin A; Fougerousse F; Leturcq F; Kaplan JC; Garcia L; Danos O
    Science; 2004 Dec; 306(5702):1796-9. PubMed ID: 15528407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Injection of a recombinant AAV serotype 2 into canine skeletal muscles evokes strong immune responses against transgene products.
    Yuasa K; Yoshimura M; Urasawa N; Ohshima S; Howell JM; Nakamura A; Hijikata T; Miyagoe-Suzuki Y; Takeda S
    Gene Ther; 2007 Sep; 14(17):1249-60. PubMed ID: 17581597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dystrophic phenotype of canine X-linked muscular dystrophy is mitigated by adenovirus-mediated utrophin gene transfer.
    Cerletti M; Negri T; Cozzi F; Colpo R; Andreetta F; Croci D; Davies KE; Cornelio F; Pozza O; Karpati G; Gilbert R; Mora M
    Gene Ther; 2003 May; 10(9):750-7. PubMed ID: 12704413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exon-skipping therapy for Duchenne muscular dystrophy.
    Nakamura A; Takeda S
    Neuropathology; 2009 Aug; 29(4):494-501. PubMed ID: 19486303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse.
    Lu QL; Mann CJ; Lou F; Bou-Gharios G; Morris GE; Xue SA; Fletcher S; Partridge TA; Wilton SD
    Nat Med; 2003 Aug; 9(8):1009-14. PubMed ID: 12847521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of an HLA-A*0201-restricted epitopic peptide from human dystrophin: application in duchenne muscular dystrophy gene therapy.
    Ginhoux F; Doucet C; Leboeuf M; Lemonnier FA; Danos O; Davoust J; Firat H
    Mol Ther; 2003 Aug; 8(2):274-83. PubMed ID: 12907150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene therapy: the 'pro-sense' approach to Duchenne muscular dystrophy.
    van Deutekom JC
    Eur J Hum Genet; 2005 May; 13(5):518-9. PubMed ID: 15714219
    [No Abstract]   [Full Text] [Related]  

  • 12. In vivo targeted repair of a point mutation in the canine dystrophin gene by a chimeric RNA/DNA oligonucleotide.
    Bartlett RJ; Stockinger S; Denis MM; Bartlett WT; Inverardi L; Le TT; thi Man N; Morris GE; Bogan DJ; Metcalf-Bogan J; Kornegay JN
    Nat Biotechnol; 2000 Jun; 18(6):615-22. PubMed ID: 10835598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Restoration of all dystrophin protein interactions by functional domains in trans does not rescue dystrophy.
    Gardner KL; Kearney JA; Edwards JD; Rafael-Fortney JA
    Gene Ther; 2006 May; 13(9):744-51. PubMed ID: 16307000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term expression of full-length human dystrophin in transgenic mdx mice expressing internally deleted human dystrophins.
    Ferrer A; Foster H; Wells KE; Dickson G; Wells DJ
    Gene Ther; 2004 Jun; 11(11):884-93. PubMed ID: 14985788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetics. Hopping to a better protein.
    Pennisi E
    Science; 2008 Dec; 322(5907):1454-5. PubMed ID: 19056949
    [No Abstract]   [Full Text] [Related]  

  • 16. Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy.
    Harper SQ; Hauser MA; DelloRusso C; Duan D; Crawford RW; Phelps SF; Harper HA; Robinson AS; Engelhardt JF; Brooks SV; Chamberlain JS
    Nat Med; 2002 Mar; 8(3):253-61. PubMed ID: 11875496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic strategies for Duchenne and Becker dystrophies.
    Voisin V; de la Porte S
    Int Rev Cytol; 2004; 240():1-30. PubMed ID: 15548414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene therapy for duchenne muscular dystrophy: expectations and challenges.
    Rodino-Klapac LR; Chicoine LG; Kaspar BK; Mendell JR
    Arch Neurol; 2007 Sep; 64(9):1236-41. PubMed ID: 17846262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exon skipping with morpholino oligomers: new treatment option for cardiomyopathy in Duchenne muscular dystrophy?
    Bauer R; Katus HA; Müller OJ
    Cardiovasc Res; 2010 Feb; 85(3):409-10. PubMed ID: 20008475
    [No Abstract]   [Full Text] [Related]  

  • 20. Gene therapy progress and prospects: Duchenne muscular dystrophy.
    Foster K; Foster H; Dickson JG
    Gene Ther; 2006 Dec; 13(24):1677-85. PubMed ID: 17066097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.